A primary antibody can be very useful for the detection of biomarkers for diseases such as cancer, diabetes, Parkinson’s and Alzheimer’s disease and they are used for the study of absorption, distribution, metabolism, and excretion (ADME) and multi-drug resistance (MDR) of therapeutic agents.
Primary antibodies play a crucial role in the detection of cancer biomarkers, enabling researchers to identify and quantify specific proteins associated with various cancer types. By using techniques such as immunohistochemistry and western blotting, scientists can visualize tumor markers that aid in early diagnosis and personalized treatment strategies. At AREX, we provide a range of high-quality primary antibodies validated for cancer research, supporting the ongoing efforts to improve diagnostic accuracy and treatment outcomes for cancer patients.
Studying Neurological Disorders
In the study of neurological disorders such as Parkinson’s and Alzheimer’s disease, primary antibodies are invaluable for detecting and characterizing the pathological proteins involved. These antibodies help researchers understand the molecular mechanisms underlying these diseases and facilitate the development of targeted therapies. AREX offers specialized primary antibodies that are essential for neuroscience research, enabling scientists to advance their understanding of neurodegenerative diseases and develop effective treatment options.
ADME Studies
The study of absorption, distribution, metabolism, and excretion (ADME) is critical for understanding how therapeutic agents behave in the body. Primary antibodies are utilized in various assays to investigate the pharmacokinetics of drugs and their metabolites, providing insights into their efficacy and safety profiles. AREX supports ADME studies by providing validated primary antibodies that can help researchers evaluate drug interactions and optimize therapeutic formulations, ultimately enhancing drug development processes.
Investigating Multi-Drug Resistance
Multi-drug resistance (MDR) poses a significant challenge in cancer treatment and infectious disease management. Primary antibodies are employed to study the expression of resistance-related proteins, enabling researchers to uncover the mechanisms that contribute to MDR. By identifying potential therapeutic targets, scientists can develop strategies to overcome resistance and improve treatment efficacy. AREX is committed to providing high-quality antibodies that facilitate research in MDR, helping to drive innovations in overcoming treatment challenges.
Product List
